Innovation Becoming Standard of Care: IL-17 Inhibitors In The Management of Spondyloarthritis
Free
Log In
Overview
In this lecture, Prof. Xenofon Baraliakos and Dennis McGonagle will discuss the recent results on IL-17 Inhibitor efficacy and safety for the management of patients with axial Spondyloarthritis and Psoriatic Arthritis
This Activity for
- Resident / Fellow
- Physician
What I will learn?
1. To discuss the efficacy and safety on IL-17 Inhibitors for the management of patients with Axial Spondyloarthritis and Psoriatic Arthritis.
2. To discuss the value of IL-17A inhibition through real life clinical cases in axSpA and PsA
3. To share Up-To-Date PsA recommendations presenting the available evidence supporting the use of IL-17 Inhibitor in PsA and axSpA as well as use in clinical practice.
About Organizer
- Virtual Medical Academy
Additional items to the activity
| Optional Details | Type | Fee |
|---|---|---|
| Innovation Becoming Standard of Care: IL-17 Inhibitors In The Management of Spondyloarthritis Certificate | Certificate | Free |
VAT 15% Included